BBIXF:OTC-Bonus BioGroup Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.03

Change

-0.01 (-25.00)%

Market Cap

USD 0.07B

Volume

3.55K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 564.56B
CMXHF CSL Limited

N/A

USD 89.03B
CSLLY CSL Ltd

N/A

USD 84.45B
UCBJF UCB SA

N/A

USD 25.40B
UCBJY UCB SA ADR

N/A

USD 24.49B
ARGNF argenx SE

N/A

USD 22.81B
GNMSF Genmab A/S

N/A

USD 18.12B
WXIBF WuXi Biologics

N/A

USD 7.17B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B

ETFs Containing BBIXF

QCLN:F First Trust Nasdaq Clean .. 7.61 % 0.00 %

N/A

USD 0.02B
QCLN:XETRA First Trust Nasdaq Clean .. 7.61 % 0.00 %

N/A

USD 0.02B
QCLN:LSE First Trust Nasdaq Clean .. 7.38 % 0.00 %

N/A

USD 0.02B
QCLU:LSE First Trust Nasdaq® Clea.. 7.38 % 0.00 %

N/A

USD 0.02B
DRUP:F Lyxor Index Fund - Lyxor .. 1.83 % 0.00 %

N/A

USD 0.18B
MIDF 1.54 % 0.00 %

N/A

N/A
QTUM Defiance Quantum 0.00 % 0.65 %

N/A

USD 0.25B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.00% 82% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.00% 82% B 89% A-
Trailing 12 Months  
Capital Gain 50.00% 88% B+ 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.00% 88% B+ 87% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 343.34% 87% B+ 92% A
Dividend Return 343.34% 87% B+ 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,394.14% 10% F 6% D-
Risk Adjusted Return 14.34% 62% D 49% F
Market Capitalization 0.07B 67% D+ 53% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector